Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Phase: Phase 1/Phase 2
Diagnosis: Prostate Cancer
NCT ID: NCT01317199
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-229
This research is being done to test an investigational product called Muscadine Plus in the treatment of men who have received initial therapy (surgery and or radiation, cryotherapy or brachytherapy) for prostate cancer and are experiencing a rise in their prostate-specific antigens (PSA) level.
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth-Israel Deaconess Medical Center
Mary-Ellen Taplin, MD,
Dana-Farber Cancer Institute
Glenn Bubley, MD,
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute:
Judith Prisby, 617-632-5068,
Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060
- Histologically or cytologically confirmed adenocarcinoma of the prostate.
- Undergone definitive treatment (surgery, surgery with radiation therapy, cryotherapy,
radiation therapy or brachytherapy) for the primary prostate tumor.
- Rising PSA on a minimum of 3 time points (including screening psa) within the 12
months prior to study initiation.
- > 18 years of age.
- Life expectancy of greater than 6 months.
- ECOG performance status 0, 1 or 2.
- Testosterone level of ≥1.5 ng/mL at screening.
- Adequate kidney, liver and bone marrow function
- Agrees to abstain from other commercially available MP products while participating
in this study.
- Subject's use of other dietary/herbal supplements (e.g. saw palmetto, selenium, etc)
has been stable for at least 2 months prior to screening and the subject agrees not
to stop or change the dose(s) while participating in the study.
- Signed a written informed consent document and agrees to comply with requirements of
- Known radiographic evidence of metastatic disease, except for presence of positive
lymph nodes from the surgical pathology. Pelvic/intraperitoneal lymph nodes less than
2.0 cm maybe considered nonspecific and the patient would be eligible
- Receipt of any therapies that modulate testosterone levels (e.g., androgen
ablative/anti-androgen therapy, 5 alpha reductase inhibitors) for a minimum of 6
months prior to study
- Prior or concomitant treatment with experimental drugs, high dose steroids, or any
other cancer treatment within 4 weeks prior to the first dose of the study product
- Consumption of Muscadine Plus over the past 2 months
- Known allergy to muscadine grapes or ellagic acid
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
- Negative PSA doubling time (1 time point may be excluded per 3e inclusion criteria)